Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
Heghine Khachatryan/LinkedIn
Apr 5, 2026, 18:05

Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared International Society on Thrombosis and Haemostasis’s post on LinkedIn:

”Rethinking Hemostatic Targets in Pregnancy: A Paradigm Shift in von Willebrand Disease Management

Emerging evidence published in the International Society on Thrombosis and Haemostasis Journal of Thrombosis and Haemostasis (JTH) challenges long-standing prophylactic thresholds in pregnant women with von Willebrand disease.

The study highlights a critical recalibration of peripartum hemostatic strategies:

  • Higher third-trimester thresholds for initiating prophylaxis (<80 IU/dL vs <50 IU/dL)
  • More ambitious peak targets at delivery (≥150 IU/dL vs ≥100 IU/dL)
  • Universal consideration of tranexamic acid across all deliveries, rather than selective use

These findings reflect a broader shift—from reactive bleeding control toward proactive hemostatic optimization.

Importantly, pregnancy represents a unique physiological stress test of the coagulation system, where even “borderline” factor levels may prove insufficient under the hemostatic challenge of delivery. This study reinforces the concept that traditional thresholds may underestimate true bleeding risk in women with VWD.

From a clinical standpoint, this raises several implications:

  • Should we redefine prophylactic cut-offs globally, particularly in resource-variable settings?
  • Are we adequately integrating dynamic risk stratification (phenotype, bleeding history, obstetric factors)?
  • Could standardized use of antifibrinolytics reduce variability in postpartum hemorrhage outcomes?

This work contributes to a growing body of evidence advocating for precision-guided hemostasis in obstetric care, where individualized targets—not static thresholds—drive management.

At Hemostasis Today, we view this as part of a necessary evolution: from protocol-driven care to data-informed, patient-specific hemostatic stewardship.”

Quoting International Society on Thrombosis and Haemostasis’s post:

”New Journal of Thrombosis and Haemostasis (JTH) research: Does higher-dosed clotting factor prophylaxis reduce postpartum hemorrhage in women with von Willebrand disease? ”

Title: Higher-dosed clotting factor prophylaxis fails to reduce postpartum hemorrhage in women with von Willebrand disease: findings from the observational PRegnancy and Inherited bleeding DisordErS study

Authors: Anne de Vaan, Jeroen Eikenboom, Marieke Kruip, Marieke Punt, Saskia Schols, Floor Heubel-Moenen, Michiel Coppens, Laurens Nieuwenhuizen, Anja Mäkelburg, Marjolein Peters, Hans Duvekot, Annemieke Middeldorp, Kitty Bloemenkamp, Roger Schutgens, Titia Lely, Karin van Galen

Read the Full Article on Journal of Thrombosis and Haemostasis

Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease

Other posts featuring Heghine Khachatryan on Hemostasis Today.

Anja Mäkelburg Anne de Vaan Annemieke Middeldorp Floor Heubel-Moenen Hans Duvekot Health Heghine Khachatryan Hematology Hemostasis News Hemostasis Today International Society on Thrombosis and Haemostasis Jeroen Eikenboom Karin van Galen Kitty Bloemenkamp Laurens Nieuwenhuizen Marieke Kruip Marieke Punt Marjolein Peters Medicine Michiel Coppens Pregnancy Roger Schutgens Saskia Schols Titia Lely Von Willebrand Disease
NewsFeed